Centessa Pharmaceuticals Limited (CNTA) News
Filter CNTA News Items
CNTA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CNTA News Highlights
- CNTA's 30 day story count now stands at 2.
- Over the past 7 days, the trend for CNTA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest CNTA News From Around the Web
Below are the latest news stories about Centessa Pharmaceuticals plc that investors may wish to consider to help them evaluate CNTA as an investment opportunity.
Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney DiseaseBOSTON and LONDON, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the “Company”), together with its subsidiary Palladio Biosciences, Inc. (“Palladio”), today announced it has started dosing of the first subject in its pivotal Phase 3 clinical trial (“ACTION Study”) evaluating lixivaptan as a potential treatment for Autosomal Dominant Polycystic Kidney Disease (“ADPKD”). The trial is expected to enroll approximately 1,350 subjects across more than 200 sites in over |
Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapitalIn this article, we discuss the top 10 stock picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. You can skip our detailed analysis of Akkaraju and Dybbs’ history, investment philosophy, and hedge fund performance, and go directly to the Top 5 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. Dr. Srinivas Akkaraju […] |
Do Institutions Own Centessa Pharmaceuticals Limited (NASDAQ:CNTA) Shares?Every investor in Centessa Pharmaceuticals Limited ( NASDAQ:CNTA ) should be aware of the most powerful shareholder... |
Checking In On Centessa PharmaceuticalsNo summary available. |
Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Up to $11.33Centessa Pharmaceuticals Limited (NASDAQ:CNTA) gapped up prior to trading on Tuesday . The stock had previously closed at $11.33, but opened at $11.82. Centessa Pharmaceuticals shares last traded at $12.03, with a volume of 1,219 shares changing hands. Separately, Zacks Investment Research raised Centessa Pharmaceuticals from a “hold” rating to a “buy” rating and set […] |
Centessa Pharmaceuticals (NASDAQ:CNTA) Rating Lowered to Hold at Zacks Investment ResearchCentessa Pharmaceuticals (NASDAQ:CNTA) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report released on Thursday, Zacks.com reports. According to Zacks, Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients. Centessa Pharmaceuticals plc is [] |
Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...Investment company Boxer Capital, Llc (Current Portfolio) buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, Fulcrum Therapeutics Inc, Turning Point Therapeutics Inc, sells Seagen Inc, Amarin Corp PLC, Therapeutics Acquisition Corp, , Agenus Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Boxer Capital, Llc. |
Compagnie Lombard Odier SCmA Takes $46,000 Position in Centessa Pharmaceuticals Limited (NASDAQ:CNTA)Compagnie Lombard Odier SCmA bought a new stake in Centessa Pharmaceuticals Limited (NASDAQ:CNTA) in the 3rd quarter, Holdings Channel.com reports. The fund bought 2,750 shares of the companys stock, valued at approximately $46,000. Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase [] |
Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 12-Month Low at $10.32Shares of Centessa Pharmaceuticals Limited (NASDAQ:CNTA) hit a new 52-week low on Wednesday . The company traded as low as $10.32 and last traded at $10.35, with a volume of 2183 shares trading hands. The stock had previously closed at $11.10. Separately, Zacks Investment Research downgraded Centessa Pharmaceuticals from a buy rating to a hold [] |
Centessa Pharmaceuticals (NASDAQ:CNTA) Trading 11% HigherCentessa Pharmaceuticals Limited (NASDAQ:CNTA) shares traded up 11% on Friday . The company traded as high as $12.20 and last traded at $12.20. 4,497 shares traded hands during trading, a decline of 98% from the average session volume of 200,208 shares. The stock had previously closed at $10.99. Separately, Zacks Investment Research lowered shares of [] |